Chiltern Announces Investment in Endpoint

LONDON, March 31, 2010 - Chiltern International Limited (Chiltern), a global contract research
organization (CRO) announced a strategic partnership with endpoint. With this
investment, Chiltern becomes a minority shareholder in the company
established in April 2009.

Glenn Kerkhof, Chiltern CEO, stated, "Chiltern's decision to invest in
endpoint is representative of our commitment to seek collaborations which
connect Chiltern and our clients with leading edge solutions as well as our
belief in the technology that endpoint has developed. Jon Dole and Tom
O'Connell are bringing a new level of energy and innovation to Interactive
Response Technology services to provide solutions which are meeting clients'
needs for flexibility, efficiency and savings while ensuring the highest
possible quality. We believe that endpoint has listened - and is responding -
to the industry's needs for IVR/IWR solutions and we look forward to
introducing endpoint to our customers as a Chiltern qualified vendor that
will meet their needs and exceed their expectations in a manner that mirrors
Chiltern's commitment to the same."

Jonathan Dole, endpoint CEO, stated, "Chiltern's enthusiasm and
investment affirms our confidence in the solutions we are bringing to the
marketplace. At endpoint, we are delighting our clients with approaches that
are exceeding their needs. Our experience in the IVR/IWR space, coupled with
a fresh and logical approach to systems development, is giving our customers
the agility they need in a constantly changing R&D environment. We are very
pleased to be working closely with Chiltern to identify and act on
opportunities for synergies across our two organizations."

PULSE, endpoint's fully configurable system that allows users to design
and deploy clinical trial IRT systems at a fraction of the time and cost of
other providers, was launched in January of this year. Providing both high
speed of deployment and flawless quality, PULSE simultaneously designs
systems that can be accessed via the phone, web, or mobile device.

Company profiles

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research
Organization with extensive experience conducting and staffing international
Phase I to Phase IV clinical trials across a broad range of therapeutic areas
for a wide variety of clients. Chiltern has conducted trials in more than 40
countries, has 24 offices and legal entities within 20 countries, resources
in 37 countries and employs nearly 1,400 people globally. Chiltern provides
Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and
Regulatory Affairs and Resourcing Solutions services. Further information is
available at www.chiltern.com.

About endpoint:

endpoint is an innovative company dedicated to the development of the
leading Interactive Response Technology (IVR/IWR) platforms for the life
sciences industry. endpoint's founding team members have been developing IRT
systems for clinical trials since 1998 and have deployed systems to small,
medium and large pharma and biotech companies for domestic and global studies
with experience across a broad range of therapeutic areas and global
implementations. www.endpointclinical.com

    For More Information Contact:

    Natalie Chong                      Sue Ojanen
    Marketing Director                 Marketing Associate
    Chiltern International Ltd.        Chiltern International Inc.
    171 Bath Road                      1241 Volunteer Parkway
    Slough                             Suite 950
    Berkshire SL1 4AA                  Bristol, TN 37620
    UNITED KINGDOM                     USA
    Tel: +44-(0)-1753-512-000          Tel: +1-423-968-9533
    Fax: +44-(0)-1753-511-116          Fax: +1-423-968-3567
    Email:
     natalie.chong@chiltern.com        Email: sue.ojanen@chiltern.com

    endpoint Contact :
    Rich Mullikin, APR
    Marketing Director
    endpoint
    690 Texas Street
    San Francisco, CA 94107
    USA
    Tel: +1-925-779-9115
    Email:
     rmullikin@endpointclinical.com

Natalie Chong, Marketing Director, +44-(0)-1753-512-000, Fax, +44-(0)-1753-511-116, natalie.chong at chiltern.com, or Sue Ojanen Marketing Associate, +1-423-968-9533, Fax, +1-423-968-3567, sue.ojanen at chiltern.com, both of Chiltern International Ltd.; or Rich Mullikin, APR, Marketing Director of endpoint, +1-925-779-9115, rmullikin at endpointclinical.com